| Primary |
| Chronic Lymphocytic Leukaemia |
39.3% |
| T-cell Prolymphocytic Leukaemia |
9.8% |
| Product Used For Unknown Indication |
9.0% |
| Large Granular Lymphocytosis |
8.2% |
| Hairy Cell Leukaemia |
7.4% |
| Graft Versus Host Disease |
5.7% |
| Cll |
3.3% |
| Non-hodgkin's Lymphoma |
3.3% |
| B-cell Chronic Lymphocytic Leukemia |
2.5% |
| Chronic Graft Versus Host Disease |
2.5% |
| Antibiotic Therapy |
1.6% |
| Hodgkin's Disease |
1.6% |
| Prolymphocytic Leukaemia |
1.6% |
| Chemotherapy |
0.8% |
| Clostridium Difficile Colitis |
0.8% |
| Depression |
0.8% |
| Drug Use For Unknown Indication |
0.8% |
| Leukaemia |
0.8% |
|
| Lymphopenia |
11.1% |
| Pyrexia |
8.3% |
| Respiratory Failure |
8.3% |
| Upper Gastrointestinal Haemorrhage |
8.3% |
| Leukaemic Infiltration Hepatic |
5.6% |
| Pain |
5.6% |
| Pancytopenia |
5.6% |
| Serratia Infection |
5.6% |
| Sinus Tachycardia |
5.6% |
| Transfusion Reaction |
5.6% |
| Treatment Noncompliance |
5.6% |
| Agranulocytosis |
2.8% |
| Anaemia Haemolytic Autoimmune |
2.8% |
| Asthenia |
2.8% |
| Blood Creatinine Increased |
2.8% |
| Bone Marrow Failure |
2.8% |
| Coombs Positive Haemolytic Anaemia |
2.8% |
| Cystitis Noninfective |
2.8% |
| Cytolytic Hepatitis |
2.8% |
| Drug Ineffective |
2.8% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
27.3% |
| Antifungal Prophylaxis |
9.9% |
| Drug Use For Unknown Indication |
9.9% |
| Antiviral Prophylaxis |
7.9% |
| Product Used For Unknown Indication |
6.9% |
| Prophylaxis |
6.4% |
| Non-hodgkin's Lymphoma |
4.5% |
| Adult T-cell Lymphoma/leukaemia |
3.4% |
| Large Granular Lymphocytosis |
3.4% |
| Hepatosplenic T-cell Lymphoma |
3.0% |
| Cll |
2.8% |
| T-cell Prolymphocytic Leukaemia |
2.8% |
| Hairy Cell Leukaemia |
2.4% |
| Fluid Retention |
1.7% |
| Pleural Mesothelioma |
1.7% |
| Premedication |
1.7% |
| Acute Graft Versus Host Disease |
1.1% |
| Graft Versus Host Disease |
1.1% |
| Malignant Lymphoid Neoplasm |
1.1% |
| Stem Cell Transplant |
1.1% |
|
| Neutropenia |
9.8% |
| Pyrexia |
8.9% |
| Lymphopenia |
8.0% |
| Neutrophil Count Decreased |
7.1% |
| Transaminases Increased |
7.1% |
| Vomiting |
6.3% |
| Death |
5.4% |
| Thrombocytopenia |
5.4% |
| Wheezing |
5.4% |
| Disease Progression |
4.5% |
| Lymphocyte Count Decreased |
4.5% |
| Tumour Lysis Syndrome |
4.5% |
| Pneumonia |
3.6% |
| Sepsis |
3.6% |
| Myelodysplastic Syndrome |
2.7% |
| Nausea |
2.7% |
| Off Label Use |
2.7% |
| Renal Failure |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
| Zygomycosis |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.2% |
| Chronic Lymphocytic Leukaemia |
16.9% |
| Prophylaxis Against Graft Versus Host Disease |
13.6% |
| Graft Versus Host Disease |
10.3% |
| Drug Use For Unknown Indication |
5.3% |
| Large Granular Lymphocytosis |
4.9% |
| Stem Cell Transplant |
4.1% |
| T-cell Prolymphocytic Leukaemia |
4.1% |
| Multiple Myeloma |
3.7% |
| Anaemia Of Malignant Disease |
2.1% |
| Hypertension |
2.1% |
| Idiopathic Thrombocytopenic Purpura |
2.1% |
| Antifungal Prophylaxis |
1.6% |
| Non-hodgkin's Lymphoma |
1.6% |
| Pain |
1.6% |
| Asthenia |
1.2% |
| C-reactive Protein Increased |
1.2% |
| Chimerism |
1.2% |
| Myelofibrosis |
1.2% |
| Acute Graft Versus Host Disease |
0.8% |
|
| Graft Versus Host Disease |
15.4% |
| Progressive Multifocal Leukoencephalopathy |
11.5% |
| Aplasia Pure Red Cell |
9.6% |
| Sepsis |
9.6% |
| Lymphadenopathy |
5.8% |
| Thrombotic Microangiopathy |
5.8% |
| Acute Myeloid Leukaemia |
3.8% |
| Aspartate Aminotransferase Increased |
3.8% |
| Death |
3.8% |
| Haemorrhagic Anaemia |
3.8% |
| Lung Neoplasm |
3.8% |
| Multi-organ Failure |
3.8% |
| Pneumonia |
3.8% |
| Therapeutic Response Decreased |
3.8% |
| Acute Myeloid Leukaemia Recurrent |
1.9% |
| Alanine Aminotransferase Increased |
1.9% |
| Chronic Graft Versus Host Disease |
1.9% |
| Cryptosporidiosis Infection |
1.9% |
| Fatigue |
1.9% |
| Febrile Neutropenia |
1.9% |
|
